Skip to main
GRI
GRI logo

GRI Stock Forecast & Price Target

GRI Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GRI Bio Inc. maintains an attractive valuation, with significant upside potential identified in their net present value analysis despite a lowered price target. The company's innovative product candidates, especially GRI-0621 and GRI-0803, address critical markets with increasing prevalence, such as autoimmune disorders and inflammatory conditions. As the incidence of idiopathic pulmonary fibrosis (IPF) continues to rise, GRI Bio's therapeutic developments position it favorably in a landscape with substantial unmet medical needs.

Bears say

GRI Bio Inc reported a net loss of $3.9 million, translating to an earnings per share (EPS) of $(7.72), which fell short of both internal estimates and consensus expectations. The company's financial outlook is characterized by significant balance sheet and liquidity risks, as well as multiple uncertainties surrounding the efficacy and safety of its product candidates in clinical trials. Furthermore, the potential for failure to secure regulatory approvals and suitable reimbursement, alongside rising competition and adverse macroeconomic factors, contributes to a negative sentiment surrounding GRI Bio's stock.

GRI has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GRI Bio Inc (GRI) Forecast

Analysts have given GRI a Strong Buy based on their latest research and market trends.

According to 2 analysts, GRI has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GRI Bio Inc (GRI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.